{"id":85,"date":"2023-12-05T10:38:18","date_gmt":"2023-12-05T09:38:18","guid":{"rendered":"https:\/\/www.gimema.it\/en\/?page_id=85"},"modified":"2024-06-19T22:51:42","modified_gmt":"2024-06-19T20:51:42","slug":"list-of-clinical-studies","status":"publish","type":"page","link":"https:\/\/www.gimema.it\/en\/list-of-clinical-studies\/","title":{"rendered":"List of clinical studies"},"content":{"rendered":"
<\/div>

In opening phase<\/h3>
\r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
Pathology<\/span><\/th>\r\n Title<\/span><\/th>\r\n Code<\/span> <\/a><\/th>\r\n Phase<\/span><\/th>\r\n Clinicaltrials.gov<\/span><\/th>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Retrospective, observational, study on the evaluation of the real-world outcome of Philadelphia-positive acute lymphoblastic leukaemia patients treated with ponatinib as first line treatment under the Italian law 648\/96 (PONA4ALL Ph+)<\/td>\r\n ALL3125<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Digital PCR per lo screening ad elevata sensibilità delle mutazionidi BCR::ABL1 nella Leucemia Mieloide Cronica (DiP-in-CML)<\/td>\r\n CML1725<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MM<\/td>\r\n Teclistamab plus autologus lymphocytes infusion for the treatment of relapse\/refractory Multiple Myeloma (TALIM) <\/td>\r\n MM0125<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MM<\/td>\r\n RISE: An Italian Registry for Infection Surveillance of patients undergoing salvage treatment with Elranatamab monotherapy<\/td>\r\n MM0426<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
MPN<\/td>\r\n Real-world Observation of Momelotinib Effectiveness in myelofibrosis (ROME)<\/td>\r\n MPN0325<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n

Open for enrollment<\/h3>
\r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
Pathology<\/span><\/th>\r\n Title<\/span><\/th>\r\n Code<\/span> <\/a><\/th>\r\n Phase<\/span><\/th>\r\n Clinicaltrials.gov<\/span><\/th>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n A Phase IIA Study of feasibility and effectiveness of inotuzumab ozogamicin (IO) in adult patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation<\/td>\r\n ALL2418<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Ancillary observational Study of post-frontline sequential treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients with dasatinib and the bispecific monoclonal antibody blinatumomab<\/td>\r\n LAL2217<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
Altri Osservazionali<\/td>\r\n Real-world mapping antithrombotic regimens in Multiple Myeloma patients on treatment (the MARMMOT Study of the GIMEMA Working Party on Hemostasis and Thrombosis)<\/td>\r\n ET0123<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
Altri Osservazionali<\/td>\r\n Salvage treatment with glofitamab in patients affected by relapsed\/refractory non Hodgkin B cell Lymphoma<\/td>\r\n IMM0123<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
Altri Osservazionali<\/td>\r\n Multicenter retrospective observational study analyzing infective complications and the clinical outcome of patients with acute lymphoblastic leukemia treated with inotuzumab ozogamicin (INO-FIRST)<\/td>\r\n INF0123<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
Altri Osservazionali<\/td>\r\n Langerhans Cell Histiocytosis in adults: a collaborative, prospective-retrospective, observational GIMEMA study<\/td>\r\n RD0120<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a post-transplant maintenance, in adult patients, aged 18-60 years, with previously untreated, de novo, favorable-intermediate-risk acute myeloid leukemia<\/td>\r\n AML1819<\/td>\r\n III<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIORATE (AML Early IntensificatiOn based on peRipheral blAsT clearance)<\/td>\r\n AML1919<\/td>\r\n III<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Prospective Multicentre Observational Study for the evaluation of clinical-hematological characteristics of familial Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDSs)<\/td>\r\n AML2120<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n Novel Approaches to Target MECOM\/EVI1 in Acute Myeloid Leukemia<\/td>\r\n AML2623<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A multicentric, prospective Study addressing the kinetics and impact on survival of Measurable Residual Disease in Acute Myeloid Leukemia patients receiving azacitidine and venetoclax<\/td>\r\n AML2723<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n Observational GIMEMA study on the outcome of acute myeloid leukemia (AML) patients treated with new drugs in real-life (Box trial)<\/td>\r\n AML2824<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A phase 2, open label, multicentre Study investigating tolerability and efficacy of gilteritinib in combination with fludarabine, cytarabine and idarubicin (FLAI) as induction therapy of newly diagnosed non-M3 FLT3-positive Acute Myeloid Leukemia<\/td>\r\n AML2924<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Survivorship Project to understAnd and to impRove long-Term outcomes for Acute myeloid leukemia patients (SPARTA): The SPARTA platform.<\/td>\r\n GIMEMA-EORTC 1621-QLG-LG (SPARTA)<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. A prospective evlaution of quality of life outcomes<\/td>\r\n QoL AML1310 <\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
APL<\/td>\r\n Treatment newly diagnosed patients with Acute Promyelocytic Leukemia, aged >12 months and <75 years, using All-Trans Retinoic Acid in combination with Idarubicin<\/td>\r\n AIDA0493<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
APL<\/td>\r\n GUIDELINES for the treatment of Acute Promyelocytic Leukemia<\/td>\r\n AIDA2000<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
APL<\/td>\r\n A Post-Authorisation Long-Term Retrospective Safety Cohort Study of Arsenic Trioxide in First Line Low- to Intermediate-Risk Acute Promyelocytic Leukaemia (APL) Patients<\/td>\r\n APL0618<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
APL<\/td>\r\n Long Term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated with Arsenic Trioxide (ATO) or Standard Chemotherapy <\/td>\r\n QoL-APL0816<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
APL<\/td>\r\n A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnosed, high-risk acute prOmyelocytic leukemia: A Prospective Evaluation of Quality of Life Outcomes<\/td>\r\n QoL-APOLLO Trial<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n An observational study to evaluate the clinical and biologic features and outcome of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens outside clinical trials in Italy<\/td>\r\n CLL1920<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Observational study on the diagnosis and management of chronic lymphocytic leukemia (CLL) in Italy by Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA)<\/td>\r\n CLL2121<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Ibrutinib for the Treatment of Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia (CLL) or CLL-like monoclonal B-cell lymphocytosis<\/td>\r\n CLL2323<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Incidence of severe COVID-19 infection in patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma who received pre-exposure prophylaxis with Tixagevimab and Cilgavimab in Italy: an observational study by the GIMEMA Working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi<\/td>\r\n CLL2423<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Outcomes of unfit patients with Chronic Lymphocytyc Leukemia (CLL) included in the front-line GIMEMA LLC1114 trial who discontinued ibrutinib due to reasons other than disease progression: a multicenter retrospective\/prospective observational study<\/td>\r\n CLL2523<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Biological and clinical efficacy of recombinant zoster vaccine (Shingrix) in patients with Chronic Lymphocytic Leukemia<\/td>\r\n CLL2624<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Observational study of pregnancy in adult patients with chronic myeloid leukemia (CML) treated with Imatinib\/Nilotinib\/Dasatinib. GIMEMA Study CML 1012\r\n <\/td>\r\n CML1012<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Front-line treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) with dasatinib. An observational multicentric study.<\/td>\r\n CML1113<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Asciminib as single agent or in combination with nilotinib in the 1st-line treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a GIMEMA-GELMC phase II study PEARL study: PotEntial of Asciminib in the eaRly treatment of CML<\/td>\r\n CML1624<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n An international field study for the reliability and validity of the Phase IV EORTC Quality of Life module for patients with Chronic Myeloid Leukemia (EORTC QLQ-CML24)<\/td>\r\n GIMEMA\/EORTC- QoLCML0916<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study to assess the complete molecular response. A Prospective evaluation of Quality of Life Outcomes<\/td>\r\n QoL CML0811<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS: A Prospective evaluation of Quality of Life Outcomes CML1516) <\/td>\r\n QoL-BEST <\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Mid to Long-term Quality of Life Effects Of imatiNIb versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)<\/td>\r\n QoL-CML0713 (LEONIDAS)<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Front-line treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) with dasatinib. An observational multicentric study. A Prospective evaluation of Quality of Life Outcomes<\/td>\r\n QoL-CML1113<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Optimizing Ponatinib USe (OPUS). A GIMEMA phase 2 study of the activity and risk profile of ponatinib, 30 mg once daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) patients resistant to imatinib: AProspective evaluation of Quality of Life Outocmes<\/td>\r\n QoL-OPUS<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
GIMEMA \/ EORTC QLG PROMOTION Project<\/td>\r\n Patient Reported Outcome Measurements Over Time In ONcology (PROMOTION) Project<\/td>\r\n GIMEMA\/EORTC QLG PROMOTION Project<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
GIMEMA\/ASDOM <\/td>\r\n Electronic data collection to improve quality of care in home-care treated patients<\/td>\r\n PROJECT GIMEMA\/ASDOM (ROMAIL)<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
ITP<\/td>\r\n Italian Adult Immune Thrombocytopenia (ITP) Registry - Investigation on a dynamic cohort of Italian patients with active ITP<\/td>\r\n ITP0918<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ITP<\/td>\r\n Biologic characterization of patients with immune thrombocytopenia (ITP)<\/td>\r\n ITP1222<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ITP<\/td>\r\n \r\nObservational Study on the outcome of patients with ITP who underwent Splenectomy after 2010\r\n<\/td>\r\n ITP1324<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MDS<\/td>\r\n Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemotherapy, according to the BM-blast proportion (ACROBAT trial)<\/td>\r\n MDS0519<\/td>\r\n III<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MDS<\/td>\r\n Prognostic significance and longitudinal assessment ofPatient-Reported Outcomes in MYelodysplastic Syndromes (PROMYS):PROMYS International Registry<\/td>\r\n PROMYS <\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
MM<\/td>\r\n Observational study on the combination of selinexor with bortezomib and dexamethasone (SVd) for the treatment of multiple myeloma patients<\/td>\r\n MM0225<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MM<\/td>\r\n Studio multicentrico osservazionale sul trattamento con terapia cellulare CAR-T in pazienti con mieloma multiplo ricaduto\/refrattario: valutazione di efficacia e sicurezza in un contesto real-world (CAR-T Mieloma Multiplo<\/td>\r\n MM0325<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
MM<\/td>\r\n CLinical decision-making, prognosis, quAlity of life and satisfaction with caRe in patIents with relapsed\/refracTory multiple mYeloma (CLARITY). <\/td>\r\n MM1016<\/td>\r\n N\/A <\/td>\r\n \r\n <\/a><\/td>\r\n \r\n <\/tr>\r\n
MPN<\/td>\r\n Observational Study Protocol REALFed: Real world evidence of fedratinib effectiveness in Myelofibrosis<\/td>\r\n MPN0123<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
MPN<\/td>\r\n Real-world ruxolitinib experience in Polycythemia Vera: REVIEW Study<\/td>\r\n MPN0224<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n

closed<\/h3>
\r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n \r\n
Pathology<\/span><\/th>\r\n Title<\/span><\/th>\r\n Code<\/span> <\/a><\/th>\r\n Phase<\/span><\/th>\r\n Clinicaltrials.gov<\/span><\/th>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Ponatinib for the management of minimal residual disease (MRD) and hematological relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients<\/td>\r\n ALL2620<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Newly diagnosed adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential treatment with ponatinib and the bispecific monoclonal antibody blinatumomab vs chemotherapy and imatinib<\/td>\r\n ALL2820<\/td>\r\n III<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Combination of ponatinib plus chemotherapy as frontline treatment for patients with BCR\/ABL1-Like Acute Lymphoblastic Leukemia (BCR\/ABL1-Like ALL) - BALLik<\/td>\r\n ALL2922<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
ALL<\/td>\r\n Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) treated according to the ALL national treatment program (DARATALL-VHR)<\/td>\r\n ALL3024<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Safety Run-In and Phase 2, Open-Label, Multicentre, Study investigating Safety, Tolerability and Effectiveness of venetoclax add in combination at fludarabine, cyratabine and idarubicine in induction therapy of new onset Non-M3 Acute Myeloid Leukemia<\/td>\r\n AML1718<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n Role of adrenomedullin in leukemic endosteal\/vascualr niches<\/td>\r\n AML2220<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms)<\/td>\r\n AML2420<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
AML<\/td>\r\n A Multicentric Phase 2 Study of venetoclax and azacitidine for the management of molecular relapse\/progression in adult NPM1-mutated Acute Myeloid Leukemia<\/td>\r\n AML2521<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Impact of treatment with targeted therapies on the generation of effective CAR T cells in patients with chronic lymphocytic leukemia<\/td>\r\n CLL2020<\/td>\r\n N\/A <\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CLL<\/td>\r\n Front-line venetoclax and obinutuzumab combination followed by venetoclax or venetoclax and zanubrutinib combination in patients with residual disease: a minimal residual disease (MRD) tailored treatment for young patients with high-risk cll. A phase 2 multicenter study (VIS trial)<\/td>\r\n CLL2222<\/td>\r\n II<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n
CML<\/td>\r\n Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response.<\/td>\r\n CML1415<\/td>\r\n IV<\/td>\r\n \r\n link<\/a><\/td>\r\n \r\n <\/tr>\r\n <\/tbody>\r\n <\/table>\r\n <\/div>\r\n \n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-85","page","type-page","status-publish","hentry","entry"],"_links":{"self":[{"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/pages\/85","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/comments?post=85"}],"version-history":[{"count":5,"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/pages\/85\/revisions"}],"predecessor-version":[{"id":640,"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/pages\/85\/revisions\/640"}],"wp:attachment":[{"href":"https:\/\/www.gimema.it\/en\/wp-json\/wp\/v2\/media?parent=85"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}